FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	. OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Senderowicz Adrian (Last) (First) (Middle) C/O CERULEAN PHARMA INC.				3	2. Issuer Name and Ticker or Trading Symbol Cerulean Pharma Inc. [CERU] 3. Date of Earliest Transaction (Month/Day/Year) 01/05/2017							below)	able) give title		10% Ow Other (s below)	ner	
35 GATE (Street) WALTHA (City)		ÍA	02451 (Zip)	4	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line)	ndividual or Joint/Group Filing (Check Applicable b) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
1. Title of Security (Instr. 3) 2. Transa Date			. Transacti	action 2A. Deemed Execution Date,		3. Transaction Code (Instr.) 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a)		ed (A) or	5. Amoun Securities Beneficia Owned Fo	s Form ally (D) o ollowing (I) (Ir		n: Direct or Indirect nstr. 4) (7. Nature of Indirect Beneficial Ownership				
						Code V	Ar	mount	(A) oi (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				Instr. 4)		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code				Expiration Dat (Month/Day/Ye		and	7. Title and of Securiti Underlying Derivative (Instr. 3 and	es g Security	8. Price of Derivative Security (Instr. 5)	rative derivative Securities 5. 5) Beneficia Owned Following Reported	e C s F ally C g (l	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expir Date	ation	Title	Amount or Number of Shares		Transaction (Instr. 4)	on(s)		
Stock Option (right to buy)	\$0.82	01/05/2017		A		60,000		(1)	01/04	1/2027	Common Stock	60,000	\$0.00	60,00	0	D	
Stock Option (right to buy)	\$0.82	01/05/2017		A		150,000		(2)	01/04	1/2027	Common Stock	150,000	\$0.00	150,00	00	D	

Explanation of Responses:

- 1. This option was granted on January 5, 2017. The shares underlying the option are scheduled to vest in equal monthly installments over four years from January 1, 2017.
- 2. This option was granted on January 5, 2017. The option is scheduled to vest as to 25% of the shares on the six-month anniversary of January 1, 2017 and as to an additional 25% of the original number of shares at the end of each six-month period of continuous service thereafter until January 1, 2019.

Remarks:

/s/ Alejandra Carvajal, as attorney-in-fact for Adrian

** Signature of Reporting Person

01/09/2017

<u>Senderowicz</u>

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.